Wednesday, September 26, 2012


There's more potentially good news from Cell Therapeutics (CTI) for lymphoma patients who've relapsed after multiple treatments and are running out of treatment options.

This week, the Seattle-based drug company announced that a Phase 1 clinical trial trial of its JAK2 inhibitor drug Pacritinib (or SB1518) for patients with any type of Hodgkin's or non-Hodgkin's lymphoma, except Burkitt's or CNS lymphoma, has yielded positive results for patients who had relapsed following a median of five prior therapies. 
The trial, whose results were published this month in the Journal of Clinical Oncology, showed encouraging anti-tumor ability in half of the trial's 34 patients, according to a report in The Wall Street Journal's MarketWatch.

What I like most about this new treatment, in addition to the fact that half the patients in the study saw a reduction in tumor size between 4 percent and 70 percent, is its evidently low toxicity compared to other JAK inhibitors.

Patients reported only mild to moderate gastrointestinal (GI) side effects - even at high doses. I'm always on the lookout for less toxic treatments for patients - this one's worth keeping an eye on.

This news comes just weeks after CTI's launch of another lymphoma drug, Pixvuri, in Europe. A clinical trial of Pixvuri, a treatment for non-Hodgkin's B-cell lymphomas, is underway in the United States and is still open for patients. 

For more information about that trial you can click here

As for
the Pacritinib trial, the results suggest this treatment has potential therapeutic value "despite the extensive degree of prior therapy and refractory nature of the disease among the patients who were enrolled in this trial," said Steven E. Brenner, CTI's chief medical officer, in a statement on the company's website.

Pacritinib is an oral, once-a-day treatment called a tyrosine kinase inhibitor that works against mutations in kinases that are directly related to the development of a variety of blood-related cancers including lymphoma, myeloproliferative disorders, and leukemia.

Pacritinib has already demonstrated encouraging results in phase 1 and 2 studies for patients with myelofibrosis. A phase 3 study is planned.


  1. There's outcomes were distributed for the current month in the Journal of Clinical Oncology. Notwithstanding the way that a large portion of the patients in the study saw a lessening in tumor measure between 4 percent and 70 percent, is its apparently low danger contrasted with other JAK inhibitors. This news comes weeks after CTI's dispatch of another lymphoma sedate, Pixvuri, in Europe.

    1. Thanks for sharing that. Who are you?